+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD



Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD



Expert Review of Respiratory Medicine 10(7): 767-780



Long-acting β2-agonists [LABAs] and long-acting muscarinic antagonists [LAMAs]) are primary therapies for chronic obstructive pulmonary disease (COPD). Despite improvements in lung function and patient-reported outcomes (PROs) with these therapies, there is room to optimize outcomes further. Combined use of LABAs and LAMAs is recommended when symptoms are not improved with a single agent, and LABA/LAMA fixed-dose combinations (FDCs) are at the forefront of drug development in COPD. This review focusses on the three LABA/LAMA FDCs (indacaterol/glycopyrrolate(1) [IND/GLY] 27.5/15.6 µg twice daily, umeclidinium/vilanterol [UMEC/VI] 62.5/25 µg once daily and tiotropium/olodaterol [Tio/Olo] 5/5 µg once daily approved in the US. Phase III clinical trials have shown benefits in lung function, dyspnea and health status with FDCs of IND/GLY, UMEC/VI and Tio/Olo versus placebo and monotherapies. Expert commentary: Data from recent studies of three LABA/LAMA combinations, reviewed here, indicate that dual bronchodilation may be beneficial above and beyond both the monotherapies and LABA/ICS combinations, in providing improvements in lung function and PROs for patients with COPD, which may encourage a shift away from the use of ICS in COPD management, in particular for non-exacerbating patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057737440

Download citation: RISBibTeXText

PMID: 27223863

DOI: 10.1080/17476348.2016.1190276


Related references

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 13: 3115-3130, 2018

A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. Expert Opinion on PharmacoTherapy 18(17): 1833-1843, 2017

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clinicoeconomics and Outcomes Research 8: 667-674, 2016

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 12: 907-922, 2017

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 13: 3203-3231, 2018

LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. Evidence-BasedMedicine21(6):222, 2016

LAMA/LABA fixed dose combination for treatment of COPD. Nihon Rinsho. Japanese Journal of Clinical Medicine 74(5): 820-826, 2016

Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?. European Clinical Respiratory Journal 2:, 2015

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety 17(5): 509-517, 2018

Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. Chest 155(6): 1158-1165, 2019

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. International Journal of Chronic Obstructive Pulmonary Disease 14: 531-546, 2019

Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects. Pulmonary Pharmacology and Therapeutics 53: 33-38, 2018

An update on LAMA/LABA combinations for COPD. Drug and Therapeutics Bulletin 55(1): 2-5, 2017

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. Bmc Pulmonary Medicine 14: 178, 2014

COPD: LAMA / LABA fixed combination more effective than separately. Praxis 105(3): 167-168, 2016